210 related articles for article (PubMed ID: 34576075)
1. C5a Activates a Pro-Inflammatory Gene Expression Profile in Human Gaucher iPSC-Derived Macrophages.
Serfecz JC; Saadin A; Santiago CP; Zhang Y; Bentzen SM; Vogel SN; Feldman RA
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576075
[TBL] [Abstract][Full Text] [Related]
2. Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease.
Pandey MK; Burrow TA; Rani R; Martin LJ; Witte D; Setchell KD; Mckay MA; Magnusen AF; Zhang W; Liou B; Köhl J; Grabowski GA
Nature; 2017 Mar; 543(7643):108-112. PubMed ID: 28225753
[TBL] [Abstract][Full Text] [Related]
3. An unexpected player in Gaucher disease: The multiple roles of complement in disease development.
Pandey MK; Grabowski GA; Köhl J
Semin Immunol; 2018 Jun; 37():30-42. PubMed ID: 29478824
[TBL] [Abstract][Full Text] [Related]
4. Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1-associated Parkinson's disease.
Kumar M; Srikanth MP; Deleidi M; Hallett PJ; Isacson O; Feldman RA
Hum Mol Genet; 2023 May; 32(11):1888-1900. PubMed ID: 36752535
[TBL] [Abstract][Full Text] [Related]
5. Gaucher iPSC-derived macrophages produce elevated levels of inflammatory mediators and serve as a new platform for therapeutic development.
Panicker LM; Miller D; Awad O; Bose V; Lun Y; Park TS; Zambidis ET; Sgambato JA; Feldman RA
Stem Cells; 2014 Sep; 32(9):2338-49. PubMed ID: 24801745
[TBL] [Abstract][Full Text] [Related]
6. Novel beta-glucocerebrosidase chaperone compounds identified from cell-based screening reduce pathologically accumulated glucosylsphingosine in iPS-derived neuronal cells.
Naito Y; Sakamoto S; Kojima T; Homma M; Tanaka M; Matsui H
SLAS Discov; 2023 Oct; 28(7):344-349. PubMed ID: 37369311
[TBL] [Abstract][Full Text] [Related]
7. A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism.
Aflaki E; Borger DK; Moaven N; Stubblefield BK; Rogers SA; Patnaik S; Schoenen FJ; Westbroek W; Zheng W; Sullivan P; Fujiwara H; Sidhu R; Khaliq ZM; Lopez GJ; Goldstein DS; Ory DS; Marugan J; Sidransky E
J Neurosci; 2016 Jul; 36(28):7441-52. PubMed ID: 27413154
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterisation of small molecule C5aR1 inhibitors in human cells reveals biased activities for signalling and function.
Li XX; Lee JD; Massey NL; Guan C; Robertson AAB; Clark RJ; Woodruff TM
Biochem Pharmacol; 2020 Oct; 180():114156. PubMed ID: 32682759
[TBL] [Abstract][Full Text] [Related]
9. Gaucher Disease-Induced Pluripotent Stem Cells Display Decreased Erythroid Potential and Aberrant Myelopoiesis.
Sgambato JA; Park TS; Miller D; Panicker LM; Sidransky E; Lun Y; Awad O; Bentzen SM; Zambidis ET; Feldman RA
Stem Cells Transl Med; 2015 Aug; 4(8):878-86. PubMed ID: 26062980
[TBL] [Abstract][Full Text] [Related]
10. Gaucher disease iPSC-derived osteoblasts have developmental and lysosomal defects that impair bone matrix deposition.
Panicker LM; Srikanth MP; Castro-Gomes T; Miller D; Andrews NW; Feldman RA
Hum Mol Genet; 2018 Mar; 27(5):811-822. PubMed ID: 29301038
[TBL] [Abstract][Full Text] [Related]
11. Elevated Dkk1 Mediates Downregulation of the Canonical Wnt Pathway and Lysosomal Loss in an iPSC Model of Neuronopathic Gaucher Disease.
Srikanth MP; Feldman RA
Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33287247
[TBL] [Abstract][Full Text] [Related]
12. Ras-Related Protein Rab5a Regulates Complement C5a Receptor Trafficking, Chemotaxis, and Chemokine Secretion in Human Macrophages.
Wu KC; Condon ND; Hill TA; Reid RC; Fairlie DP; Lim J
J Innate Immun; 2023; 15(1):468-484. PubMed ID: 36882040
[TBL] [Abstract][Full Text] [Related]
13. Recombinant C5a stimulates transcription rather than translation of interleukin-1 (IL-1) and tumor necrosis factor: translational signal provided by lipopolysaccharide or IL-1 itself.
Schindler R; Gelfand JA; Dinarello CA
Blood; 1990 Oct; 76(8):1631-8. PubMed ID: 2207333
[TBL] [Abstract][Full Text] [Related]
14. Altered Differentiation Potential of Gaucher's Disease iPSC Neuronal Progenitors due to Wnt/β-Catenin Downregulation.
Awad O; Panicker LM; Deranieh RM; Srikanth MP; Brown RA; Voit A; Peesay T; Park TS; Zambidis ET; Feldman RA
Stem Cell Reports; 2017 Dec; 9(6):1853-1867. PubMed ID: 29198828
[TBL] [Abstract][Full Text] [Related]
15. Complement C5a-C5aR1 signalling drives skeletal muscle macrophage recruitment in the hSOD1
Wang HA; Lee JD; Lee KM; Woodruff TM; Noakes PG
Skelet Muscle; 2017 Jun; 7(1):10. PubMed ID: 28571586
[TBL] [Abstract][Full Text] [Related]
16. mTOR hyperactivity mediates lysosomal dysfunction in Gaucher's disease iPSC-neuronal cells.
Brown RA; Voit A; Srikanth MP; Thayer JA; Kingsbury TJ; Jacobson MA; Lipinski MM; Feldman RA; Awad O
Dis Model Mech; 2019 Oct; 12(10):. PubMed ID: 31519738
[TBL] [Abstract][Full Text] [Related]
17. Complement C5a Induces Pro-inflammatory Microvesicle Shedding in Severely Injured Patients.
Karasu E; Demmelmaier J; Kellermann S; Holzmann K; Köhl J; Schmidt CQ; Kalbitz M; Gebhard F; Huber-Lang MS; Halbgebauer R
Front Immunol; 2020; 11():1789. PubMed ID: 32983087
[TBL] [Abstract][Full Text] [Related]
18. The Complement System Component C5a Produces Thermal Hyperalgesia via Macrophage-to-Nociceptor Signaling That Requires NGF and TRPV1.
Shutov LP; Warwick CA; Shi X; Gnanasekaran A; Shepherd AJ; Mohapatra DP; Woodruff TM; Clark JD; Usachev YM
J Neurosci; 2016 May; 36(18):5055-70. PubMed ID: 27147658
[TBL] [Abstract][Full Text] [Related]
19. Targeting the Complement-Sphingolipid System in COVID-19 and Gaucher Diseases: Evidence for a New Treatment Strategy.
Trivedi VS; Magnusen AF; Rani R; Marsili L; Slavotinek AM; Prows DR; Hopkin RJ; McKay MA; Pandey MK
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430817
[TBL] [Abstract][Full Text] [Related]
20. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease.
Horowitz M; Braunstein H; Zimran A; Revel-Vilk S; Goker-Alpan O
Adv Drug Deliv Rev; 2022 Aug; 187():114402. PubMed ID: 35764179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
